Recordati Rare Diseases Inc., the makers of CYSTADROPS, launched a website to support the launch of the eye treatment...
Read moreBy Cystinosis Research Network
October 13, 2020
In a statement from Leadient Biosciences on October 9th, the company announced an availability shortage may impact cystinosis patients...
Read moreBy Cystinosis Research Network
October 9, 2020
In April, the Cystinosis Network Europe adapted their international conference to the restrictions set forth by COVID-19. The result...
Read moreBy Cystinosis Research Network
September 29, 2020
The next phase of clinical development for the CF10 prodrug to treat cystinosis has been announced. The Cystinosis Foundation...
Read moreThe Neuromuscular Clinic at Massachusetts General Hospital (MGH) led by Dr. Reza Seyedsadjadi, is currently enrolling participants for a...
Read moreEmory University in Atlanta, Georgia, is actively recruiting for the Cohort 0 control groupin the CYStem clinical trial. While...
Read moreA new chapter in cystinosis research has begun. Novartis has officially opened the next phase of its CYStem Phase...
Read moreFor our families using Cystadrops, we received the following information from Recordati. This update was in response to direct...
Read moreNovartis has announced the Phase I/II CYStem clinical trial will recruit children ages 2-5 with nephropathic cystinosis. The trial...
Read more